Physician profile
Seema Kumar
NPI 1700082534
$1,037.79
in general payments reported to CMS, 2019-2025
25 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.77 · 2020: $28.77 · 2021: $410 · 2022: $127 · 2023: $49.41 · 2024: $187 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $197.43 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $132.59 | 2021-2022 | |
| Kyowa Kirin, INC. | $69.69 | 2024-2025 | Nourianz |
| Neurocrine Biosciences, INC. | $68.93 | 2020-2024 | Ingrezza |
| Amgen INC. | $61.68 | 2022-2024 | Prolia, Evenity |
| Lilly USA, LLC | $61.48 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.11 | 2021-2025 | Ofev |
| Avion Pharmaceuticals | $38.45 | 2022 | |
| Biogen, INC. | $36.49 | 2021-2024 | Vumerity |
| Novo Nordisk INC | $26.10 | 2025 | Rybelsus, Ozempic |
| Corium, LLC | $25.88 | 2022-2023 | Adlarity |
| Emd Serono, INC. | $25.77 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.72 | 2025 | Onpattro |
| Beta Bionics, INC. | $24.32 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Eisai INC. | $23.29 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $20.00 | 2021 | |
| Genentech USA, INC. | $19.95 | 2024 | Ocrevus Zunovo |
| Pfizer INC. | $18.27 | 2024 | |
| Sunovion Pharmaceuticals INC. | $17.58 | 2021 | |
| Tandem Diabetes Care, INC. | $16.94 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $16.54 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.32 | 2024 | Ongentys |
| Abbott Laboratories | $15.46 | 2025 | Freestyle Libre 3 |
| Genzyme Corporation | $13.34 | 2021 | |
| Supernus Pharmaceuticals, INC. | $11.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.